Table 7.
Non-randomized studies with combinations of pegylated liposomal doxorubicin (PLD) and platinum agents
| Author | Drugs/dose | PFI mts | No. pts | RR (%) | PFS mts | % Grade 3/4 toxicity/patient |
|||
|---|---|---|---|---|---|---|---|---|---|
| Hgb | Neu | PLT | HFS | ||||||
| Tas83 | PLD (50 mg/m2) d1 | ≥6 | 22 | 62.0 | – | 18 | 41 | 0 | 9 |
| CDDP (60 mg/m2) d1, q28 | |||||||||
| Vorobiof84 | PLD (50 mg/m2) d1 | ≥6 | 29 | 76.2 | 9 | 52.3 | 38 | 9.5 | |
| JM8 (AUC 5) d1, q28 | |||||||||
| du Bois85 | PLD (40 mg/m2) d1 | ≥6 | 67 | 68 | 11.6 | 8 | 24 | 14 | 7 |
| JM8 (AUC 6) d1, q28 | |||||||||
| Rapoport86 | PLD (50 mg/m2) d1 | All | 40 | 67.5 | 11.9 | 10 | 55 | 42.5 | 7.5 |
| JM8 (AUC 5) d1, q28 | 7–12 | 19 | 52.6 | 9.7 | |||||
| >12 | 21 | 81.0 | 15.1 | ||||||
| Ferrero87 | PLD (30 mg/m2) d1 | All | 96 | 62.5 | 9.4 | 12 | 51 | 26 | 0 |
| JM8 (AUC 5) d1, q28 | 7–12 | 43 | – | 7.9 | |||||
| >12 | 53 | – | 11.4 | ||||||
| Power88 | PLD (30 mg/m2) d1 | 7–12 | 58 | 46 | 10 | 7 | 21 | 17 | 1.7 |
| JM8 (AUC 5) d1, q28 | |||||||||
| Weber89 | PLD (30 mg/m2) d1 | ≥6 | 81 | 65.4 | 13.6 | 13.0 | 55.0 | 29.0 | 1.0 |
| JM8 (AUC 5) d1, q28 | 6–12 | 32 | – | 9.8 | |||||
| ≥12 | 49 | – | 14.4 | ||||||
| Nicoletto90 | PLD (30 mg/m2) d1 | <6 | 14 | 28.6 | 5.9 | 0 | 9.3 | 0 | 0 |
| OXA (70 mg/m2) d1, q28 | ≥6 | 29 | 66.7 | 9.9 | |||||
| Recchia91 | PLD (20 mg/m2) d1,2 | <6 | 13 | 32.5 | 5.8 | 5 | 38 | 8 | 0 |
| OXA (60 mg/m2) d1,2, q21 | ≥6 | 27 | 67.5 | 12.1 | |||||
| Valerio92 | PLD (30 mg/m2) | <6 | 27 | 37.0 | 7 | 17 | 15 | 15 | 0 |
| OXA (85 mg/m2) | ≥6 | 12 | 66.3 | 8.5 | |||||
| cyclophosphamide (750 mg/m2) | |||||||||
Abbreviations: CDDP, cisplatin; HFS, hand–foot syndrome; Hgb, anemia; JM8, carboplatin; Neu, neutropenia; PFI, platinum-free interval; PFS, progression-free survival; PLT, platelet toxicity; RR, response rate; OXA, oxaliplatin; q, every; d, day.